125 related articles for article (PubMed ID: 38496627)
1. Rarγ -Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer.
Felice D; Alaimo A; Bressan D; Genovesi S; Marmocchi E; Annesi N; Beccaceci G; Dalfovo D; Cutrupi F; Foletto V; Lorenzoni M; Gandolfi F; Kannan S; Verma CS; Vasciaveo A; Shen MM; Romanel A; Chiacchiera F; Cambuli F; Lunardi A
bioRxiv; 2024 Mar; ():. PubMed ID: 38496627
[TBL] [Abstract][Full Text] [Related]
2. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ; Karthaus WR; Hoover E; Liu D; Gruet A; Zhang Z; Cho H; DiLoreto R; Chhangawala S; Liu Y; Watson PA; Davicioni E; Sboner A; Barbieri CE; Bose R; Leslie CS; Sawyers CL
Nature; 2019 Jul; 571(7765):408-412. PubMed ID: 31243370
[TBL] [Abstract][Full Text] [Related]
3. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
4. Deletion of
Sribenja S; Maguire O; Attwood K; Buas MF; Palmer JR; Ambrosone CB; Higgins MJ
Am J Cancer Res; 2021; 11(6):3263-3270. PubMed ID: 34249460
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.
Albayrak G; Konac E; Ugras Dikmen A; Bilen CY
Exp Biol Med (Maywood); 2018 Aug; 243(12):990-994. PubMed ID: 30043639
[TBL] [Abstract][Full Text] [Related]
6. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation.
Gao N; Ishii K; Mirosevich J; Kuwajima S; Oppenheimer SR; Roberts RL; Jiang M; Yu X; Shappell SB; Caprioli RM; Stoffel M; Hayward SW; Matusik RJ
Development; 2005 Aug; 132(15):3431-43. PubMed ID: 15987773
[TBL] [Abstract][Full Text] [Related]
8. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.
Zhang C; Wang L; Wu D; Chen H; Chen Z; Thomas-Ahner JM; Zynger DL; Eeckhoute J; Yu J; Luo J; Brown M; Clinton SK; Nephew KP; Huang TH; Li W; Wang Q
Cancer Res; 2011 Nov; 71(21):6738-6748. PubMed ID: 21900400
[TBL] [Abstract][Full Text] [Related]
9. Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.
Chen F; Li A; Gao S; Hollern D; Williams M; Liu F; VanSickle EA; Andrechek E; Zhang C; Yang C; Luo R; Xiao H
Cell Death Dis; 2014 May; 5(5):e1242. PubMed ID: 24853420
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
Sunkel B; Wu D; Chen Z; Wang CM; Liu X; Ye Z; Horning AM; Liu J; Mahalingam D; Lopez-Nicora H; Lin CL; Goodfellow PJ; Clinton SK; Jin VX; Chen CL; Huang TH; Wang Q
Nucleic Acids Res; 2016 May; 44(9):4105-22. PubMed ID: 26743006
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
12. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C
Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907
[TBL] [Abstract][Full Text] [Related]
13. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
15. The essential role of GATA transcription factors in adult murine prostate.
Xiao L; Feng Q; Zhang Z; Wang F; Lydon JP; Ittmann MM; Xin L; Mitsiades N; He B
Oncotarget; 2016 Jul; 7(30):47891-47903. PubMed ID: 27374105
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
17. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer.
Yang YA; Yu J
Genes Dis; 2015 Jun; 2(2):144-151. PubMed ID: 26114156
[TBL] [Abstract][Full Text] [Related]
18. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.
Gastaldi S; Sassi F; Accornero P; Torti D; Galimi F; Migliardi G; Molyneux G; Perera T; Comoglio PM; Boccaccio C; Smalley MJ; Bertotti A; Trusolino L
Oncogene; 2013 Mar; 32(11):1428-40. PubMed ID: 22562252
[TBL] [Abstract][Full Text] [Related]
19. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
[TBL] [Abstract][Full Text] [Related]
20. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.
Li F; Yuan Q; Di W; Xia X; Liu Z; Mao N; Li L; Li C; He J; Li Y; Guo W; Zhang X; Zhu Y; Aji R; Wang S; Tong X; Ji H; Chi P; Carver B; Wang Y; Chen Y; Gao D
J Clin Invest; 2020 Nov; 130(11):5924-5941. PubMed ID: 32701507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
